1: Woo YR et al. (2020) Updates on the Risk of Neuropsychiatric and Gastrointestinal Comorbidities in Rosacea and Its Possible Relationship with the Gut-Brain-Skin Axis. Int J Mol Sci. 21(22):8427. DOI: 10.3390/ijms21228427.
2: Scharschmidt TC et al. (2011) Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol.147(1):123-6. DOI: 10.1001/archdermatol.2010.413
3: Chen Q et al. (2020) Association between rosacea and cardiometabolic disease: A systematic review and meta-analysis. J Am Acad Dermatol. 83(5):1331-1340. DOI: 10.1016/j.jaad.2020.04.113.
4: Pagan AD et al. (2023) Cross-Sectional Study of Psoriasis, Atopic Dermatitis, Rosacea, and Alopecia Areata Suggests Association With Cardiovascular Diseases. J Drugs Dermatol.22(6):576-58 DOI: 10.36849/JDD.7424.
5: Yamasaki K, Gallo RL. (2011) Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 15(1):12-5. DOI:10.1038/jidsymp.2011.4.
6: Yamasaki K et al. (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 13(8):975-80. DOI: 10.1038/nm1616.
7: Wang L et al. (2020) The Theranostics Role of Mast Cells in the Pathophysiology of Rosacea. Front Med (Lausanne). 6:324. DOI: 10.3389/fmed.2019.00324
8: Muto Y et al. (2014) Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 134(11):2728-2736. DOI: 10.1038/jid.2014.222
